Ritu Baral

Yasmeen Rahimi

Akash Tewari

Andrea Newkirk

Andy Chen

Eliana Merle

Jay Olson

Liisa Bayko

Prakhar Agrawal

Thomas Smith

Mayank Mamtani

Amy Li

Andrea Tan

Catherine Okoukoni

David Lebowitz

Ellie Merle

Emma Gutstein

John Walleban

John Wolleben

Kaveri Pohlman

- Novo Nordisk’s Wegovy (semaglutide 2.4mg) has been approved as the **second treatment for metabolic dysfunction-associated steatohepatitis (MASH)**, entering a market currently defined by Madrigal Pharmaceuticals’ Rezdiffra (resmetirom).  **[1157601_9cec550eb2404273bc8eb4871a7469fa_0]** 
- Despite only **42%** of physicians reporting unaided awareness of Wegovy’s approval, **nearly two-thirds (65%)** expect to prescribe it within the next three months.  **[1157601_9cec550eb2404273bc8eb4871a7469fa_0]** 
- Physicians envision distinct roles for the two therapies: **Wegovy monotherapy** is the leading approach for moderate fibrosis (F2) patients (**43%** preference), while **Rezdiffra monotherapy** is also appealing (**30%** preference).  **[1157601_9cec550eb2404273bc8eb4871a7469fa_0]** 
- For advanced fibrosis (F3) patients, the most common preference (**43%**) is for **combination therapy** using both Rezdiffra and Wegovy.  **[1157601_9cec550eb2404273bc8eb4871a7469fa_0]**

Spherix Global Insights Reports on Wegovy's MASH Approval and Physician Intent

MADRIGAL PHARMACEUTICALS (MDGL)